HIGHLIGHTS
- who: Mikhail M. Kostik from the University of Brescia, Italy have published the article: Standard and increased canakinumab dosing to quiet macrophage activation syndrome in children with systemic juvenile idiopathic arthritis, in the Journal: (JOURNAL)
- what: The authors report the use of increased doses of canakinumab in children with sJIA who initially were treated with standard doses of canakinumab for treatment of MAS.
- how: The number of systemic features was calculated according to published consensus opinion .
SUMMARY
The clinical and laboratory features of sJIA and MAS during disease onset . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.